January 19, 2022
A total of 23 drugs (APIs)/41 products will see their prices pared by special re-pricing rules in the FY2022 price revision in April, including Takeda Pharmaceutical’s acid reducer Takecab (vonoprazan) and all GLP-1 agents in injectable forms. A roster of...read more